Fig. 3: KH-3 inhibits breast cancer cell growth and destabilizes HuR targets.

a, b MTT-based cytotoxicity of KH-3 against a panel of TNBC cell lines (a) and MDA-MB-231 cells, sgControl and two HuR KO clones (b). c–h Half-life of Bcl-2, Msi2 and XIAP mRNA in MDA-MB-231 (c–e) and SUM159 (f–h) cells treated with 5 μg/mL actinomycin D together with DMSO, KH-3 or KH-3B. Data are mean ± SD from n = 3 independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA).